About Belay Diagnostics

Belay provides innovative and dynamic diagnostic tools for evaluating suspected central nervous system tumors. Their broader vision is to save lives through the discovery and delivery of diagnostic insights.

Patient Stories: Belay Diagnostics Summit™ 2.0, Ascent™, and Vantage™ CSF Liquid Biopsy Tests
Help other patients by sharing your experience with CSF Liquid Biopsy Tests from Belay Diagnostics.

Summit 2.0 is advanced molecular testing that analyzes a sample of your cerebrospinal fluid (CSF) to help diagnose central nervous system (CNS) tumors. Because it uses CSF from a routine lumbar puncture, Summit 2.0 can help bridge the gap where other tumor detection options have limitations:

Summit 2.0 looks for specific genes and genomic changes associated with brain and spinal cord cancers. Detecting that certain genes are present, or confirming they’re absent, helps indicate the tumor type and whether it may be benign. The genes investigated are listed in your Belay Diagnostics report. Clinicians use test results and guidelines (for example, The National Comprehensive Cancer Network) to help inform diagnosis, select therapies and clinical trials, and monitor treatment. In short, identifying genomic alterations helps your physician detect and manage CNS malignancies.​

Vantage is an additional CSF‑based test that evaluates MGMT promoter methylation status, a biomarker used in certain CNS tumors. A positive MGMT methylation result is generally associated with a more favorable prognosis and can help your care team select therapies where a better response is likely.

Vantage can be ordered together with Summit™ and uses the same CSF specimen, providing complementary information to guide treatment decisions without additional invasive procedures.

When Your Doctor Recommends Testing By Belay Diagnostics:

Patients Should Have Access to Healthcare: